{"id":116211,"date":"2021-07-12T09:36:56","date_gmt":"2021-07-12T02:36:56","guid":{"rendered":"https:\/\/nawacita.co\/?p=116211"},"modified":"2021-07-12T09:36:56","modified_gmt":"2021-07-12T02:36:56","slug":"polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan","status":"publish","type":"post","link":"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/","title":{"rendered":"Polemik Vaksin Berbayar, Kimia Farma Tegaskan Tak Mencari Keuntungan"},"content":{"rendered":"

Jakarta, Nawacita<\/strong> – Pelaksana Tugas (Plt) Direktur Utama Kimia Farma Diagnostik Agus Chandra, menegaskan pihaknya tidak mencari keuntungan dalam layanan program Vaksinasi Gotong Royong (VGR) individu di sejumlah kliniknya. Ia menyebut, layanan vaksinasi berbayar tersebut dilakukan untuk mendukung percepatan program vaksinasi pemerintah.<\/p>\n

“Kami tidak memanfaatkan program Vaksin Gotong Royong individu untuk tujuan komersial, tetapi upaya kami untuk mendukung pemerintah mempercepat proses vaksinasi,” kata Agus, dalam konferensi pers secara virtual, Minggu (11\/7\/2021).<\/p>\n

Terkait harga vaksin per dosis dalam program itu, ia menjelaskan jika pemerintah telah mengaturnya melalui surat keputusan yang dikeluarkan Kementerian Kesehatan.<\/p>\n

“Harga vaksin untuk VGR individu\/perorangan sama dengan harga vaksin untuk VGR badan usaha\/badan hukum, yaitu sudah ditetapkan oleh Kementerian Kesehatan, termasuk tarif layanan penyuntikannya,” jelasnya.<\/p>\n

Lebih lanjut, ia menegaskan jika program vaksinasi berbayar tidak akan menggangu program vaksinasi gratis yang dilakukan pemerintah.<\/p>\n

Sebab, jenis vaksin yang digunakan pun berbeda dengan program vaksin gratis pemerintah yakni jenis Sinovac dan Astra Zeneca. Sementara Vaksin Gotong Royong dari Kimia Farma menggunakan vaksin Sinopharm.<\/p>\n

“Kami memastikan hal itu tidak akan mengganggu vaksinasi program yang biayanya ditanggung oleh pemerintah,” imbuhnya.<\/p>\n

Penulis: Alma Fikhasari<\/p>\n","protected":false},"excerpt":{"rendered":"

Jakarta, Nawacita – Pelaksana Tugas (Plt) Direktur Utama Kimia Farma Diagnostik Agus Chandra, menegaskan pihaknya tidak mencari keuntungan dalam layanan program Vaksinasi Gotong Royong (VGR) individu di sejumlah kliniknya. Ia menyebut, layanan vaksinasi berbayar tersebut dilakukan untuk mendukung percepatan program vaksinasi pemerintah. “Kami tidak memanfaatkan program Vaksin Gotong Royong individu untuk tujuan komersial, tetapi upaya […]<\/p>\n","protected":false},"author":1,"featured_media":103082,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13359],"tags":[39773,37685,30063],"class_list":{"0":"post-116211","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-legislatif","8":"tag-berbayar","9":"tag-ppkm","10":"tag-vaksin"},"yoast_head":"\nPolemik Vaksin Berbayar, Kimia Farma Tegaskan Tak Mencari Keuntungan - Nawacita<\/title>\n<meta name=\"description\" content=\"Vaksinasi Gotong Royong (VGR) individu di sejumlah kliniknya. Ia menyebut, layanan vaksinasi berbayar tersebut dilakukan untuk mendukung\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Polemik Vaksin Berbayar, Kimia Farma Tegaskan Tak Mencari Keuntungan - Nawacita\" \/>\n<meta property=\"og:description\" content=\"Vaksinasi Gotong Royong (VGR) individu di sejumlah kliniknya. Ia menyebut, layanan vaksinasi berbayar tersebut dilakukan untuk mendukung\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/\" \/>\n<meta property=\"og:site_name\" content=\"Nawacita\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/nawacitaco-1763136813898723\/?ref=aymt_homepage_panel\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-12T02:36:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nawacita.co\/wp-content\/uploads\/2020\/12\/3699860537.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"redaksi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@nawacit4\" \/>\n<meta name=\"twitter:site\" content=\"@nawacit4\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"redaksi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/\"},\"author\":{\"name\":\"redaksi\",\"@id\":\"https:\/\/nawacita.co\/#\/schema\/person\/599683af640858fd3b790bc37828ba57\"},\"headline\":\"Polemik Vaksin Berbayar, Kimia Farma Tegaskan Tak Mencari Keuntungan\",\"datePublished\":\"2021-07-12T02:36:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/\"},\"wordCount\":190,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/nawacita.co\/#organization\"},\"image\":{\"@id\":\"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/nawacita.co\/wp-content\/uploads\/2020\/12\/3699860537.jpg\",\"keywords\":[\"Berbayar\",\"PPKM\",\"vaksin\"],\"articleSection\":[\"LEGISLATIF\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/\",\"url\":\"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/\",\"name\":\"Polemik Vaksin Berbayar, Kimia Farma Tegaskan Tak Mencari Keuntungan - Nawacita\",\"isPartOf\":{\"@id\":\"https:\/\/nawacita.co\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/nawacita.co\/wp-content\/uploads\/2020\/12\/3699860537.jpg\",\"datePublished\":\"2021-07-12T02:36:56+00:00\",\"description\":\"Vaksinasi Gotong Royong (VGR) individu di sejumlah kliniknya. Ia menyebut, layanan vaksinasi berbayar tersebut dilakukan untuk mendukung\",\"breadcrumb\":{\"@id\":\"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/#primaryimage\",\"url\":\"https:\/\/nawacita.co\/wp-content\/uploads\/2020\/12\/3699860537.jpg\",\"contentUrl\":\"https:\/\/nawacita.co\/wp-content\/uploads\/2020\/12\/3699860537.jpg\",\"width\":600,\"height\":400,\"caption\":\"Vaksin Covid-19 Sputnik V Terampuh di Dunia.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/nawacita.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Polemik Vaksin Berbayar, Kimia Farma Tegaskan Tak Mencari Keuntungan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/nawacita.co\/#website\",\"url\":\"https:\/\/nawacita.co\/\",\"name\":\"Nawacita\",\"description\":\"Berita Kementerian, BUMN, Pemerintah dan Politik\",\"publisher\":{\"@id\":\"https:\/\/nawacita.co\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/nawacita.co\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/nawacita.co\/#organization\",\"name\":\"Nawacita\",\"url\":\"https:\/\/nawacita.co\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/nawacita.co\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/nawacita.co\/wp-content\/uploads\/2021\/10\/Logo-Nawacita-2021.png\",\"contentUrl\":\"https:\/\/nawacita.co\/wp-content\/uploads\/2021\/10\/Logo-Nawacita-2021.png\",\"width\":1676,\"height\":422,\"caption\":\"Nawacita\"},\"image\":{\"@id\":\"https:\/\/nawacita.co\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/nawacitaco-1763136813898723\/?ref=aymt_homepage_panel\",\"https:\/\/x.com\/nawacit4\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/nawacita.co\/#\/schema\/person\/599683af640858fd3b790bc37828ba57\",\"name\":\"redaksi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/nawacita.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a3ea3038dabe75a981e9a69b300b8272c74e0729c55e2f30478cde7add6c42f6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a3ea3038dabe75a981e9a69b300b8272c74e0729c55e2f30478cde7add6c42f6?s=96&d=mm&r=g\",\"caption\":\"redaksi\"},\"sameAs\":[\"nawacitaportal\",\"https:\/\/x.com\/nawacit4\"],\"url\":\"https:\/\/nawacita.co\/index.php\/author\/redaksi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Polemik Vaksin Berbayar, Kimia Farma Tegaskan Tak Mencari Keuntungan - Nawacita","description":"Vaksinasi Gotong Royong (VGR) individu di sejumlah kliniknya. Ia menyebut, layanan vaksinasi berbayar tersebut dilakukan untuk mendukung","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/","og_locale":"en_US","og_type":"article","og_title":"Polemik Vaksin Berbayar, Kimia Farma Tegaskan Tak Mencari Keuntungan - Nawacita","og_description":"Vaksinasi Gotong Royong (VGR) individu di sejumlah kliniknya. Ia menyebut, layanan vaksinasi berbayar tersebut dilakukan untuk mendukung","og_url":"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/","og_site_name":"Nawacita","article_publisher":"https:\/\/www.facebook.com\/nawacitaco-1763136813898723\/?ref=aymt_homepage_panel","article_published_time":"2021-07-12T02:36:56+00:00","og_image":[{"width":600,"height":400,"url":"https:\/\/nawacita.co\/wp-content\/uploads\/2020\/12\/3699860537.jpg","type":"image\/jpeg"}],"author":"redaksi","twitter_card":"summary_large_image","twitter_creator":"@nawacit4","twitter_site":"@nawacit4","twitter_misc":{"Written by":"redaksi","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/#article","isPartOf":{"@id":"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/"},"author":{"name":"redaksi","@id":"https:\/\/nawacita.co\/#\/schema\/person\/599683af640858fd3b790bc37828ba57"},"headline":"Polemik Vaksin Berbayar, Kimia Farma Tegaskan Tak Mencari Keuntungan","datePublished":"2021-07-12T02:36:56+00:00","mainEntityOfPage":{"@id":"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/"},"wordCount":190,"commentCount":0,"publisher":{"@id":"https:\/\/nawacita.co\/#organization"},"image":{"@id":"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/#primaryimage"},"thumbnailUrl":"https:\/\/nawacita.co\/wp-content\/uploads\/2020\/12\/3699860537.jpg","keywords":["Berbayar","PPKM","vaksin"],"articleSection":["LEGISLATIF"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/","url":"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/","name":"Polemik Vaksin Berbayar, Kimia Farma Tegaskan Tak Mencari Keuntungan - Nawacita","isPartOf":{"@id":"https:\/\/nawacita.co\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/#primaryimage"},"image":{"@id":"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/#primaryimage"},"thumbnailUrl":"https:\/\/nawacita.co\/wp-content\/uploads\/2020\/12\/3699860537.jpg","datePublished":"2021-07-12T02:36:56+00:00","description":"Vaksinasi Gotong Royong (VGR) individu di sejumlah kliniknya. Ia menyebut, layanan vaksinasi berbayar tersebut dilakukan untuk mendukung","breadcrumb":{"@id":"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/#primaryimage","url":"https:\/\/nawacita.co\/wp-content\/uploads\/2020\/12\/3699860537.jpg","contentUrl":"https:\/\/nawacita.co\/wp-content\/uploads\/2020\/12\/3699860537.jpg","width":600,"height":400,"caption":"Vaksin Covid-19 Sputnik V Terampuh di Dunia."},{"@type":"BreadcrumbList","@id":"https:\/\/nawacita.co\/index.php\/2021\/07\/12\/polemik-vaksin-berbayar-kimia-farma-tegaskan-tak-mencari-keuntungan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nawacita.co\/"},{"@type":"ListItem","position":2,"name":"Polemik Vaksin Berbayar, Kimia Farma Tegaskan Tak Mencari Keuntungan"}]},{"@type":"WebSite","@id":"https:\/\/nawacita.co\/#website","url":"https:\/\/nawacita.co\/","name":"Nawacita","description":"Berita Kementerian, BUMN, Pemerintah dan Politik","publisher":{"@id":"https:\/\/nawacita.co\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nawacita.co\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/nawacita.co\/#organization","name":"Nawacita","url":"https:\/\/nawacita.co\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nawacita.co\/#\/schema\/logo\/image\/","url":"https:\/\/nawacita.co\/wp-content\/uploads\/2021\/10\/Logo-Nawacita-2021.png","contentUrl":"https:\/\/nawacita.co\/wp-content\/uploads\/2021\/10\/Logo-Nawacita-2021.png","width":1676,"height":422,"caption":"Nawacita"},"image":{"@id":"https:\/\/nawacita.co\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/nawacitaco-1763136813898723\/?ref=aymt_homepage_panel","https:\/\/x.com\/nawacit4"]},{"@type":"Person","@id":"https:\/\/nawacita.co\/#\/schema\/person\/599683af640858fd3b790bc37828ba57","name":"redaksi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nawacita.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/a3ea3038dabe75a981e9a69b300b8272c74e0729c55e2f30478cde7add6c42f6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a3ea3038dabe75a981e9a69b300b8272c74e0729c55e2f30478cde7add6c42f6?s=96&d=mm&r=g","caption":"redaksi"},"sameAs":["nawacitaportal","https:\/\/x.com\/nawacit4"],"url":"https:\/\/nawacita.co\/index.php\/author\/redaksi\/"}]}},"jetpack_featured_media_url":"https:\/\/nawacita.co\/wp-content\/uploads\/2020\/12\/3699860537.jpg","jetpack_sharing_enabled":true,"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/posts\/116211","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/comments?post=116211"}],"version-history":[{"count":0,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/posts\/116211\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/media\/103082"}],"wp:attachment":[{"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/media?parent=116211"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/categories?post=116211"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/tags?post=116211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}